Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.81 |
| ▸ | SLC5A1 | P13866 | 17/20 | 0.81 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.71 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12167067 | 1.00 | SLC5A2 (0.81) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1456770 | 0.99 | SLC5A2 (0.79) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL18466622 | 0.99 | SLC5A2 (0.79) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL18466491 | 0.99 | SLC5A2 (0.79) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL12167101 | 0.99 | SLC5A2 (0.79) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL12167094 | 0.99 | SLC5A2 (0.82) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1457108 | 0.99 | SLC5A2 (0.82) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL4557748 | 0.96 | SLC5A2 (0.84) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL12167109 | 0.96 | SLC5A2 (0.84) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13380366 | 0.93 | SLC5A2 (0.79) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730131-B1 | GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2012-05-09 | — | — | EP | claimed |
| EP-2295422-A2 | Glucopyranosyl substituted benzol derivatives, pharmaceutical compositions containing these compounds, use thereof and method for their production | Boehringer Ingelheim International GmbH (DE) | 2011-03-16 | — | — | EP | claimed |
| US-20100298243-A1 | COMBINATION THERAPY WITH SGLT-2 INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-25 | — | — | US | claimed |
| CN-101534815-A | Combination therapy using SGLT-2 inhibitors and pharmaceutical compositions thereof | BOEHRINGER INGELHEIM INT BOEHR (DE) | 2009-09-16 | — | — | CN | claimed |
| US-7579449-B2 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-25 | — | — | US | claimed |
| US-20090023913-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-22 | — | — | US | claimed |
| US-11759474-B2 | Use of SGLT-2 inhibitors in the drying-off of non-human mammals | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| US-20230285432-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230140631-A1 | TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-05-04 | — | — | US | disclosed |
| US-20200085851-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2020-03-19 | — | — | US | disclosed |
| US-10442795-B2 | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-10-15 | — | — | US | disclosed |
| US-10442795-B2 | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-10-15 | — | — | US | disclosed |
| US-20180214468-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2018-08-02 | — | — | US | disclosed |
| US-20070259821-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259821-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259821-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| WO-2007093610-A1 | GLUCOPYRANOSYL-SUBSTITUTED BENZONITRILE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007025943-A2 | GLUCOPYRANOSYL-SUBSTITUTED BENZYL-BENZENE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-08 | — | — | WO | disclosed |
| WO-2006120208-A1 | PROCESSES FOR PREPARING OF GLUCOPYRANOSYL-SUBSTITUTED BENZYL-BENZENE DERIVATIVES AND INTERMEDIATES THEREIN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-16 | — | — | WO | disclosed |
| US-20050209166-A1 | Metabolic disorders like diabetes; inhibits sodium-dependent glucose cotransporter; 1-chloro-2-(4-cyclopentyloxybenzyl)-4-( beta -D-glucopyranos-1-yl)-benzene | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023913-A1 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | UGGT1, G6PD, SLC5A1 | SLC5A2 5/4885SLC5A1 3/4885ADRA2A 401/4885 |
| US-20050209166-A1 | Metabolic disorders like diabetes; inhibits sodium-dependent glucose cotransporter; 1-chloro-2-(4-cyclopentyloxybenzyl)-4-( beta -D-glucopyranos-1-yl)-benzene | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 458/4885 |
| US-20230285432-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | SLC5A1, SLC5A2, DPP4 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 757/4885 |
| US-20070259821-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | UGGT1, UGT1A4, SLC5A1 | SLC5A2 5/4885SLC5A1 3/4885ADRA2A 2034/4885 |
| US-20180214468-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 667/4885 |
| US-20100298243-A1 | COMBINATION THERAPY WITH SGLT-2 INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS | SLC5A1, SLC5A2, GLP1R | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 373/4885 |
| US-11759474-B2 | Use of SGLT-2 inhibitors in the drying-off of non-human mammals | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 596/4885 |
| US-10442795-B2 | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein | UGGT1, B3GAT3, B4GALT1 | SLC5A2 120/4885SLC5A1 111/4885ADRA2A 2019/4885 |
| US-20230140631-A1 | TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS | SLC5A2, SLC5A1, GPR119 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 567/4885 |
| US-20200085851-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | SLC5A1, SLC5A2, DPP4 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.